Purchased common stock, pre-funded warrants and Series A and Series B common warrants in the PIPE private placement, together with Perceptive Xontogeny Venture Fund II, LP, for an aggregate purchase price of $20.0 million
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Mark Litton
Also a director
PRESIDENT and CEO
Title from the Form 4 dated Apr 9, 2026
|
58 | Not stated | $1,423,814 | |
|
Robert Renninger
Chief Financial Officer
|
42 |
Since 2025
1 year
|
Not reported | |
|
Javier San Martin
Chief Medical Officer
|
61 |
Since 2024
2 years
|
$810,134 | |
|
Kevin Church
chief scientific officer
|
41 |
Since 2023
3 years
|
Not reported | |
|
Mark Worthington
general counsel
|
60 |
Since 2021
5 years
|
$731,477 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchased common stock, pre-funded warrants and Series A and Series B common warrants in the PIPE private placement, together with Perceptive Xontogeny Venture Fund II, LP, for an aggregate purchase price of $20.0 million
Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors
Board designation right under the PIPE Securities Purchase Agreement; designee appointed to our board of directors
Exclusive license to develop and commercialize oral lasofoxifene outside Asia and certain Middle East countries; consideration includes third-party service provider payments and $75,000 per month payments to Sermonix
Securities purchase agreement under which we issued a pre-funded warrant to purchase 5,502,402 shares of common stock at an exercise price of $0.001 per share, with related registration rights
Loading...